Current gold standard therapeutic strategies for T2DM target insulin resistance or cell dysfunction as their core mechanisms of action
You may choose to: To exercise your choices, you may: If you opt-out using the directions and/or mechanisms provided in a specific type of communication, please be aware that you may only stop receiving that type of communication unless you exercise another option as described herein
6 The mechanistic story is a self-reinforcing loop
Patients with Type 2 diabetes have many other drug treatment options, including other GLP-1 receptor agonists like Mounjaro (tirzepatide) and Trulicity (dulaglitude)
Wolever TMS, Tosh SM, Spruill SE, Jenkins AL, Ezatagha A, Duss R, Johnson J, Chu YF, Steinert RE
What regions lead the receptor agonist market